


Mental health problems in people with learning disabilities
Appendix N: GRADE evidence profiles for all studies

Quality assessment							Number of patients		Effect		Quality	Importance
Number of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Methylphenidate	placebo	Relative (95% CI)	Absolute (95% CI)		
ADHD (follow up: mean 16 weeks; assessed with: Connors' ADHD index [parent rated])												
1	randomised trials	not serious	not serious	not serious	serious ¹	none	61	61	-	MD 3.3 fewer (6.79 fewer to 0.19 more)	⊕⊕⊕○ MODERATE	CRITICAL
ADHD (follow up: mean 16 weeks; assessed with: Connors' ADHD index [teacher rated])												
1	randomised trials	not serious	not serious	not serious	serious ¹	none	61	61	-	MD 4.1 fewer (7.57 fewer to 0.63 fewer)	⊕⊕⊕○ MODERATE	CRITICAL
Hyperactivity (follow up: mean 16 weeks; assessed with: Connors' hyperactivity scale [parent rated])												
1	randomised trials	not serious	not serious	not serious	serious ²	none	61	61	-	MD 1.5 fewer (3.44 fewer to 0.44 more)	⊕⊕⊕○ MODERATE	CRITICAL
Hyperactivity (follow up: mean 16 weeks; assessed with: Connors' hyperactivity scale [teacher rated])												
1	randomised trials	not serious	not serious	not serious	serious ¹	none	61	61	-	MD 2.6 fewer (4.68 fewer to 0.52 fewer)	⊕⊕⊕○ MODERATE	CRITICAL
'Improved' or 'better' (follow up: mean 16 weeks; assessed with: Clinical Global Impressions-Improvement)												
1	randomised trials	not serious	not serious	not serious	serious ¹	none	24/61 (39.3%)	4/61 (6.6%)	RR 6.00 (2.21 to 16.26)	328 more per 1000 (from 79 more to 1000 more)	⊕⊕⊕○ MODERATE	CRITICAL
Quality of life – not reported												

Quality assessment							Number of patients		Effect		Quality	Importance
Number of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Methylphenidate	placebo	Relative (95% CI)	Absolute (95% CI)		
-	-	-	-	-	-	-					-	CRITICAL
Community participation and meaningful occupation – not reported												
-	-	-	-	-	-	-					-	CRITICAL
Weight (follow up: mean 16 weeks; assessed with: kg)												
1	randomised trials	not serious	not serious	not serious	serious ²	none	61	61	-	MD 4.2 kg fewer (10.25 fewer to 1.85 more)	 MODERATE	IMPORTANT

1. Sample size less than optimal information size (<400 for continuous outcomes or <300 for dichotomous outcomes).
2. Confidence intervals cross one minimally important difference. Sample size less than optimal information size (<400 for continuous outcomes or <300 for dichotomous outcomes).